Nucynta 01
Nucynta
Product Images NDC 69865-265
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Nucynta (NDC 69865-265). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Depo Nf Sub, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Nucynta 02
This is a chart that indicates the percentage of patients who reported improvement in pain from baseline after a 15-week treatment period. There are two lines on the chart, one for Placebo and one for Nucynta ER. The percentage improvement in pain ranges from 0 to 100 on the y-axis and there are tick marks indicating intervals of 10. On the x-axis, there are tick marks indicating intervals of 10 for percent improvement in pain from baseline. There are also additional tick marks indicating percentiles within these intervals (e.g., 5, 15, 25, etc.).*
Nucynta 03
This is a chart showing the percentage of patients who improved their pain levels after using a medication, likely called Nucynta ER), compared to a placebo. The chart shows the percentage of improvement at various points between 0 and 100, and records the improvement after 12 weeks of use.*
Nucynta 04
This is a chart that displays the percentage of patients who improved in pain from the baseline after 12 weeks of a double-blind period. The chart compares the improvement between a placebo group and an NUCYNTA® ER group. The percentage of improvement is shown for different levels of pain relief, ranging from 10% to 100%.*
Nucynta 05
Nucynta ER (tapentadol) is an extended-release tablet used for moderate to severe pain relief. Each tablet contains 50 mg of tapentadol and should be swallowed whole, without chewing or crushing. Keep the medication out of reach of children and protected from moisture. Federal law prohibits transferring the drug to anyone other than the patient it was prescribed for. See the accompanying medication guide for each patient to follow the prescribed dosage. No other information is available.*
Nucynta 06
Nucynta 07
This is the packaging of Nucynta ER, an extended-release tablet containing tapentadol. Each tablet contains 150mg of tapentadol and should be swallowed whole without crushing or dissolving. Federal laws prohibit the transfer of this drug to anyone other than the patient for whom it was prescribed. The medication guide should also be given to each patient. It is recommended to keep the drug away from moisture and out of reach of children. The storage temperature should be between 15°C-30°C (50°F-36°F) or up to 25°C (77°F) as permitted by USP. No other useful information is available.*
Nucynta 08
Nucynta ER is a tablet containing 200mg of tapentadol, sold in a package of 60 tablets. It is an extended-release medication only available with a prescription. It is necessary to swallow the tablets whole, and they should not be chewed or dissolved. According to federal law, this drug cannot be transferred to anyone other than the patient for whom it was prescribed. A medication guide should be given to each patient along with the prescription. Dosage information is included in the package insert, and it should be kept out of the reach of children. A product code and a revision date are included at the bottom of the page.*
Nucynta 09
Nucynta ER (tapentadol) is an extended-release tablet used for managing pain. Each tablet contains 250mg tapentadol and should be swallowed whole, without chewing, crushing or dissolving. Transfer of the drug to any person other than the patient for whom it was prescribed is prohibited by federal law. The medication guide should be given to each patient. The drug should be stored at room temperature, protected from moisture and out of reach of children. For full prescribing information, refer to the package insert. No further information is available from this text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
